Navigation Links
DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion

AUSTIN, Texas, Oct. 6 /PRNewswire/ -- DiFUSION Technologies Inc., a medical device company focused on the development and commercialization of its proprietary CleanFUZE™ anti-microbial technology for orthopedic implants, announced today the 510(k) clearance of its new Xiphos™ line of posterior interbody devices indicated for intervertebral body fusion of the lumbar spine, from L2 to SI, in skeletally mature patients who have had six months of non-operative treatment.  The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. The Xiphos™ System of implants is also indicated for use to replace a vertebral body that has been resected or excised (i.e. partial or total vertebrectomy) due to tumor or trauma/fracture.  The system is intended for the thoracolumbar spine (from T1 to L5) and is intended for use with supplemental internal fixation.

"This clearance marks a milestone in DiFUSION's commercial pathway. Not only does it provide us an early stage revenue source, the Xiphos line is also a platform on which we will continue to develop our CleanFUZE line of fusion devices," said John Kaelblein, President of DiFUSION Technologies.

Spinal fusion procedures are common orthopedic procedures used to treat disorders of the spine including degenerative conditions, deformities, spinal trauma and tumors. In fact, in 2009 over 500,000 spinal fusion procedures were performed in the US, a figure growing by over four percent annually. One of the implants often used in these procedures is the interbody fusion device, the market for which is now approaching $1 billion. The Xiphos line of interbody devices is DiFUSION's entry into this segment.

"The Xiphos posterior interbody platform includes an array of implant shapes and sizes for varying patient anatomy and surgical preference allowing for posterior, posterior oblique and transforaminal approaches," remarked Dr. Jami Hafiz, PhD, VP of Development for DiFUSION Technologies. "We really focused on developing a best in class series of implants that could serve as a platform for future development."

About DiFUSION Technologies

Founded in 2008 in Austin, Texas, DiFUSION Technologies, Inc. is a medical device company focused on reducing the rising incidence of surgical site infections in orthopedic and spine surgery through the development of a suite of patented antimicrobial orthobiologic polymeric implants. Initially focusing on the multi-billion dollar spinal implant market, the company has developed a technology with applicability across a variety of orthopedic segments using well characterized implants with benefits for the patient, surgeon, hospital and payer. For more information about DiFUSION Technologies, visit

CleanFUZE orthobiologic polymers have not been approved by the US FDA. CleanFUZE is not available for sale within the United States.

SOURCE DiFUSION Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
(Date:11/30/2015)... Medical Systems (NYSE: VAR ) has signed a Memorandum of ... the largest hospital chain in India , to ... country. The MoU was signed by Dr. K. Prabakar , ... Varian,s India managing director, in ... intends to deploy its Access to Care program by leveraging the ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
(Date:11/30/2015)... -- Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare ... , a country of over 122 million people. --> ... million people. --> It offers companies, investors, policymakers, and ... into the second largest pharma and healthcare market in ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort to ... to access life-saving information provided directly from top experts in mesothelioma, in 2016 ... conferences in three major cities: Houston, San Francisco, and Chicago. , “For ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... hunger cravings that drive people to overeat are not necessarily caused by real hunger, ... brain that the stomach needs food. He notes that, while many patients are aware ...
(Date:11/30/2015)... FL (PRWEB) , ... November 30, 2015 , ... ... a comparison chart and ingredient list of its hemorrhoid ointment to its website. ... effective pain relief for people suffering from hemorrhoids. Adding the comparison chart and ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar tests ... adults, according to a new study by researchers at the School of Public Health ... Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published 32nd Annual ... (NPDS) reveals that in 2014, someone called a poison center about every 11 ... which were human exposure cases. , The American Association of Poison Control Centers ...
Breaking Medicine News(10 mins):